5-(3-carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid,
CGS 23131,
LY 223982,
LY 233978 disodium salt,
LY-223982,
SK and F 107324,
SK and F-107324,
SKF 107324,
LY223982,
117423-74-2,
LY-223982,
Cgs 23131,
UNII-XG52JC545T,
CHEMBL49302,
XG52JC545T,
LY 233978 Disodium salt,
Skf 107324,
SK&F 107324,
LY 223982,
AC1O61A0,
GTPL3415,
SCHEMBL7202040,
SCHEMBL7202044,
ZINC3780900,
[3H]CGS23131,
BDBM50001611,
PDSP1_000574,
PDSP2_000572,
[3H]-CGS23131,
[3H]CGS 23131,
5-(3-Carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)benzenepropanoic acid,
HY-112737,
LY-333982,
RT-013625,
CS-0063235,
L000032,
J-003621,
LY223982 (Synonyms: CGS23131; SKF107324),
(E)-3-{3-(2-Carboxy-ethyl)-4-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-benzoyl}-benzoic acid,
(Z)-3-{3-(2-Carboxy-ethyl)-4-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-benzoyl}-benzoic acid,
3-[3-(2-carboxyethyl)-4-[(E)-6-(4-methoxyphenyl)hex-5-enoxy]benzoyl]benzoic acid,
3-{3-(2-Carboxy-ethyl)-4-[(E)-6-(4-methoxy-phenyl)-hex-5-enyloxy]-benzoyl}-benzoic acid,
3-{3-(2-Carboxy-ethyl)-4-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-benzoyl}-benzoic acid,
3-{[3-(2-carboxyethyl)-4-{[(5E)-6-(4-methoxyphenyl)hex-5-en-1-yl]oxy}phenyl]carbonyl}benzoic acid,
3-{3-(2-Carboxy-ethyl)-4-[6-(4-methoxy-phenyl)-hex-5-enyloxy]-benzoyl}-benzoic acid (BT223982),
Benzenepropanoic acid, 5-(3-carboxybenzoyl)-2-((6-(4-methoxyphenyl)-5-hexenyl)oxy)-, (E)-,
Benzenepropanoic acid, 5-(3-carboxybenzoyl)-2-[[(5E)-6-(4-methoxyphenyl)-5-hexen-1-yl]oxy]-,
D01SJS,
D0U9JL,
SYZSSLLFRVDRHL-QPJJXVBHSA-N,
AXL-1717,
IGF-1 inhibitors, Axelar/Biovitrum,
BVT-51004,
CGS-23131,
C30-H30-O7,
CID6444688,
SKF-107324,
IGF-1 inhibitors, Karolinska/Biovitrum,
[3H]-SKF 107324,
LY-223980,
LY-255253,
Insulin-like growth factor 1 inhibitors, Axelar/Biovitrum,